Cargando…
Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report
BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently adminis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125806/ https://www.ncbi.nlm.nih.gov/pubmed/35606850 http://dx.doi.org/10.1186/s12948-022-00173-0 |
_version_ | 1784712009469657088 |
---|---|
author | Delgado-Prada, Ana Borrás, Julián Farzanegan, Roxana Torres Gorriz, María Cruz Germán-Sánchez, Adrián Cervera Aznar, Raquel Raducan, Isabela Castelló, Jose Vicente Sanchez-Hernandez, Alfredo Enrique, Ernesto |
author_facet | Delgado-Prada, Ana Borrás, Julián Farzanegan, Roxana Torres Gorriz, María Cruz Germán-Sánchez, Adrián Cervera Aznar, Raquel Raducan, Isabela Castelló, Jose Vicente Sanchez-Hernandez, Alfredo Enrique, Ernesto |
author_sort | Delgado-Prada, Ana |
collection | PubMed |
description | BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently administered regimens for ifosfamide are fractionated doses for 3 to 5 days, high-dose intravenous bolus, and continuous infusion over 24 to 72 h. Hypersensitivity reactions to ifosfamide plus mesna are not frequently described in the literature. Moreover, no reports exist concerning desensitization for this chemotherapy combination. CASE PRESENTATION: A 47-year-old man with stage IV renal sarcoma was treated with the combination of ifosfamide and mesna every 3 weeks in a 4-consecutive-day infusion protocol. During the second cycle of chemotherapy, he presented acute cutaneous symptoms. A 12-step desensitization protocol was proposed in view of the lack of knowledge of the possible hypersensitivity reactions to this combination of chemotherapy agents, and the multiple difficulties found during the study of the case. CONCLUSIONS: The 12-step desensitization protocol was well tolerated. Therefore, it is an appropriate and safe option in the case of suspected allergy to ifosfamide plus mesna. |
format | Online Article Text |
id | pubmed-9125806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91258062022-05-24 Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report Delgado-Prada, Ana Borrás, Julián Farzanegan, Roxana Torres Gorriz, María Cruz Germán-Sánchez, Adrián Cervera Aznar, Raquel Raducan, Isabela Castelló, Jose Vicente Sanchez-Hernandez, Alfredo Enrique, Ernesto Clin Mol Allergy Case Report BACKGROUND: Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and increase the therapeutic dose. The most frequently administered regimens for ifosfamide are fractionated doses for 3 to 5 days, high-dose intravenous bolus, and continuous infusion over 24 to 72 h. Hypersensitivity reactions to ifosfamide plus mesna are not frequently described in the literature. Moreover, no reports exist concerning desensitization for this chemotherapy combination. CASE PRESENTATION: A 47-year-old man with stage IV renal sarcoma was treated with the combination of ifosfamide and mesna every 3 weeks in a 4-consecutive-day infusion protocol. During the second cycle of chemotherapy, he presented acute cutaneous symptoms. A 12-step desensitization protocol was proposed in view of the lack of knowledge of the possible hypersensitivity reactions to this combination of chemotherapy agents, and the multiple difficulties found during the study of the case. CONCLUSIONS: The 12-step desensitization protocol was well tolerated. Therefore, it is an appropriate and safe option in the case of suspected allergy to ifosfamide plus mesna. BioMed Central 2022-05-23 /pmc/articles/PMC9125806/ /pubmed/35606850 http://dx.doi.org/10.1186/s12948-022-00173-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Delgado-Prada, Ana Borrás, Julián Farzanegan, Roxana Torres Gorriz, María Cruz Germán-Sánchez, Adrián Cervera Aznar, Raquel Raducan, Isabela Castelló, Jose Vicente Sanchez-Hernandez, Alfredo Enrique, Ernesto Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
title | Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
title_full | Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
title_fullStr | Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
title_full_unstemmed | Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
title_short | Cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
title_sort | cutaneous reaction to ifosfamide plus mesna treated with desensitization challenge: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125806/ https://www.ncbi.nlm.nih.gov/pubmed/35606850 http://dx.doi.org/10.1186/s12948-022-00173-0 |
work_keys_str_mv | AT delgadopradaana cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT borrasjulian cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT farzaneganroxana cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT torresgorrizmariacruz cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT germansanchezadrian cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT cerveraaznarraquel cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT raducanisabela cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT castellojosevicente cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT sanchezhernandezalfredo cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport AT enriqueernesto cutaneousreactiontoifosfamideplusmesnatreatedwithdesensitizationchallengeacasereport |